Curated News
By: NewsRamp Editorial Staff
July 25, 2024
Annovis Bio Receives U.S. Patent for Lead Drug Candidate Targeting Neurodegenerative Diseases
Discuss on Reddit
Discuss on LinkedIn
Discuss on SubstackTLDR
- Annovis Bio announced a new patent for buntanetap, targeting multiple neurotoxic proteins to improve brain function.
- The patent covers methods of treating acute traumatic brain injuries and preventing nerve cell death with buntanetap's inhibition of neurotoxic proteins.
- Buntanetap's potential benefits for brain trauma victims could improve the quality of life for patients with neurodegenerative diseases.
- Buntanetap, formerly known as Posiphen, targets neurodegeneration by inhibiting the formation of multiple neurotoxic proteins, improving synaptic transmission and reducing neuroinflammation.
Impact - Why it Matters
This news matters as it highlights a significant milestone in the development of a drug targeting neurodegenerative diseases. The patent's coverage of methods for treating traumatic brain injuries and preventing nerve cell death could potentially impact the lives of patients suffering from brain trauma and neurodegenerative conditions.
Summary
Annovis Bio (NYSE: ANVS), a late-stage drug-platform company, announced the receipt of U.S. Patent No. 12,042,482 for its lead drug candidate, buntanetap, targeting neurodegenerative diseases. The patent covers methods of treating acute traumatic brain injuries and preventing nerve cell death by inhibiting the formation of neurotoxic proteins.
CEO Maria Maccecchini expressed excitement about the milestone, emphasizing buntanetap's potential benefits for victims of brain trauma. The company's innovative approach aims to restore brain function and improve the quality of life for patients with neurodegenerative diseases.
Source Statement
This curated news summary relied on this press release disributed by InvestorBrandNetwork (IBN). Read the source press release here, Annovis Bio Receives U.S. Patent for Lead Drug Candidate Targeting Neurodegenerative Diseases
